Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 456 participants.

Also called NCT04707768

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 456 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04707768
Other papers using this trial's data
  • Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD American journal of kidney diseases : the official journal of the National Kidney Foundation, 2025-04 DOI, PubMed 39521398

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04707768. Randomized; no masking; primary purpose treatment. Start 2021-06-18 (actual); primary completion 2023-01-06 (actual). Results posted on 2025-01-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Condition
Anemia Associated With Chronic Kidney Disease (CKD (chronic kidney disease))
Intervention (Drug)
Vadadustat
Intervention (Drug)
Mircera®
Lead sponsor
Akebia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct04707768
Content hash
ad569a236c80d6b482c5a7135f878371d523aeb844f80a37fa5a1f5cb297f229